Abstract
Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are human neuromuscular disorders associated with mutations of simple repetitive sequences in affected genes. The abnormal expansion of CTG repeats in the 3′-UTR of the DMPK gene elicits DM1, whereas elongated CCTG repeats in intron 1 of ZNF9/CNBP triggers DM2. Pathogenesis of both disorders is manifested by nuclear retention of expanded repeat-containing RNAs and aberrant alternative splicing. The precise determination of absolute numbers of mutant RNA molecules is important for a better understanding of disease complexity and for accurate evaluation of the efficacy of therapeutic drugs. We present two quantitative methods, Multiplex Ligation-Dependent Probe Amplification and droplet digital PCR, for studying the mutant DMPK transcript (DMPKexpRNA) and the aberrant alternative splicing in DM1 and DM2 human tissues and cells. We demonstrate that in DM1, the DMPKexpRNA is detected in higher copy number than its normal counterpart. Moreover, the absolute number of the mutant transcript indicates its low abundance with only a few copies per cell in DM1 fibroblasts. Most importantly, in conjunction with fluorescence in-situ hybridization experiments, our results suggest that in DM1 fibroblasts, the vast majority of nuclear RNA foci consist of a few molecules of DMPKexpRNA.
Highlights
In DM adult skeletal muscle abnormal expression of embryonic splicing isoforms has been reported for a few hundred genes[4]
Two methods based on Multiplex Ligation-Dependent Probe Amplification (MLPA) and droplet digital PCR were used for quantification of RNA biomarkers of DM pathogenesis, including aberrant alternative splicing and DMPKexpRNA copy number
We demonstrate that two quantitative methods, MLPA and droplet digital PCR (ddPCR), can be successfully applied to accurately measure RNA biomarkers of DM pathogenesis which are mechanistically very informative
Summary
In DM adult skeletal muscle abnormal expression of embryonic splicing isoforms has been reported for a few hundred genes[4]. We calculate concentration of DMPK mRNA in human DM1 samples using a novel ddPCR approach which is an absolute quantification method Optimization of this technique to develop a further biomarker of DM1 is the second aim of this current work. Two methods based on Multiplex Ligation-Dependent Probe Amplification (MLPA) and droplet digital PCR (ddPCR) were used for quantification of RNA biomarkers of DM pathogenesis, including aberrant alternative splicing and DMPKexpRNA copy number. MLPA and ddPCR are reliable dosage quantification methods and various applications include large mutation detection, genotyping of copy number variants, evaluation of NGS library exome enrichment efficiency, methylation analysis, and high-sensitivity gene expression studies[11,12,13,14,15,16,17,18]. The normalized signals from MLPA probes are proportional to the dosage of their targets
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have